These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

972 related articles for article (PubMed ID: 17079814)

  • 21. Comparison of tumor volumes as determined by pathologic examination and FDG-PET/CT images of non-small-cell lung cancer: a pilot study.
    Yu J; Li X; Xing L; Mu D; Fu Z; Sun X; Sun X; Yang G; Zhang B; Sun X; Ling CC
    Int J Radiat Oncol Biol Phys; 2009 Dec; 75(5):1468-74. PubMed ID: 19464822
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Variation in background intensity affects PET-based gross tumor volume delineation in non-small-cell lung cancer: the need for individualized information.
    Chen GH; Yao ZF; Fan XW; Zhang YJ; Gao HQ; Qian W; Wu KL; Jiang GL
    Radiother Oncol; 2013 Oct; 109(1):71-6. PubMed ID: 24060171
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Intra-tumour 18F-FDG uptake heterogeneity decreases the reliability on target volume definition with positron emission tomography/computed tomography imaging.
    Dong X; Wu P; Sun X; Li W; Wan H; Yu J; Xing L
    J Med Imaging Radiat Oncol; 2015 Jun; 59(3):338-45. PubMed ID: 25708154
    [TBL] [Abstract][Full Text] [Related]  

  • 24. 18F-fluorodeoxyglucose positron emission tomography/computed tomography-based radiotherapy target volume definition in non-small-cell lung cancer: delineation by radiation oncologists vs. joint outlining with a PET radiologist?
    Hanna GG; Carson KJ; Lynch T; McAleese J; Cosgrove VP; Eakin RL; Stewart DP; Zatari A; O'Sullivan JM; Hounsell AR
    Int J Radiat Oncol Biol Phys; 2010 Nov; 78(4):1040-51. PubMed ID: 20350798
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Static and moving phantom studies for radiation treatment planning in a positron emission tomography and computed tomography (PET/CT) system.
    Okubo M; Nishimura Y; Nakamatsu K; Okumura M; Shibata T; Kanamori S; Hanaoka K; Hosono M
    Ann Nucl Med; 2008 Aug; 22(7):579-86. PubMed ID: 18756360
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Assessment of interobserver reproducibility in quantitative 18F-FDG PET and CT measurements of tumor response to therapy.
    Jacene HA; Leboulleux S; Baba S; Chatzifotiadis D; Goudarzi B; Teytelbaum O; Horton KM; Kamel I; Macura KJ; Tsai HL; Kowalski J; Wahl RL
    J Nucl Med; 2009 Nov; 50(11):1760-9. PubMed ID: 19837757
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of CT and positron emission tomography/CT coregistered images in planning radical radiotherapy in patients with non-small-cell lung cancer.
    Macmanus M; D'Costa I; Everitt S; Andrews J; Ackerly T; Binns D; Lau E; Ball D; Weih L; Hicks RJ
    Australas Radiol; 2007 Aug; 51(4):386-93. PubMed ID: 17635480
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Areas of high 18F-FDG uptake on preradiotherapy PET/CT identify preferential sites of local relapse after chemoradiotherapy for non-small cell lung cancer.
    Calais J; Thureau S; Dubray B; Modzelewski R; Thiberville L; Gardin I; Vera P
    J Nucl Med; 2015 Feb; 56(2):196-203. PubMed ID: 25572091
    [TBL] [Abstract][Full Text] [Related]  

  • 29. 18F-FDG PET in planning radiation treatment of non-small cell lung cancer: where exactly is the tumor?
    Dahele MR; Ung YC
    J Nucl Med; 2007 Aug; 48(8):1402; author reply 1403. PubMed ID: 17673427
    [No Abstract]   [Full Text] [Related]  

  • 30. Risk factors for occult mediastinal metastases in clinical stage I non-small cell lung cancer.
    Lee PC; Port JL; Korst RJ; Liss Y; Meherally DN; Altorki NK
    Ann Thorac Surg; 2007 Jul; 84(1):177-81. PubMed ID: 17588407
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Breast cancer with low FDG uptake: characterization by means of dual-time point FDG-PET/CT.
    Zytoon AA; Murakami K; El-Kholy MR; El-Shorbagy E; Ebied O
    Eur J Radiol; 2009 Jun; 70(3):530-8. PubMed ID: 18395387
    [TBL] [Abstract][Full Text] [Related]  

  • 32. FDG-PET/CT imaging in assessing mucin-producing non-small cell lung cancer with pathologic correlation.
    Shim SS; Han J
    Ann Nucl Med; 2010 Jun; 24(5):357-62. PubMed ID: 20306161
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tumor volume assessment by 18F-FDG PET/CT in patients with oral cavity cancer with dental artifacts on CT or MR images.
    Baek CH; Chung MK; Son YI; Choi JY; Kim HJ; Yim YJ; Ko YH; Choi J; Cho JK; Jeong HS
    J Nucl Med; 2008 Sep; 49(9):1422-8. PubMed ID: 18703597
    [TBL] [Abstract][Full Text] [Related]  

  • 34. PET CT thresholds for radiotherapy target definition in non-small-cell lung cancer: how close are we to the pathologic findings?
    Wu K; Ung YC; Hornby J; Freeman M; Hwang D; Tsao MS; Dahele M; Darling G; Maziak DE; Tirona R; Mah K; Wong CS
    Int J Radiat Oncol Biol Phys; 2010 Jul; 77(3):699-706. PubMed ID: 19836163
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prognostic value of the quantitative metabolic volumetric measurement on 18F-FDG PET/CT in Stage IV nonsurgical small-cell lung cancer.
    Liao S; Penney BC; Zhang H; Suzuki K; Pu Y
    Acad Radiol; 2012 Jan; 19(1):69-77. PubMed ID: 22142679
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Integrated fluorine-18 fluorodeoxyglucose (18F-FDG) PET/CT compared to standard contrast-enhanced CT for characterization and staging of pulmonary tumors eligible for surgical resection.
    Quaia E; Tona G; Gelain F; Lubin E; Pizzolato R; Boscolo E; Bussoli L
    Acta Radiol; 2008 Nov; 49(9):995-1004. PubMed ID: 18651256
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A technique of using gated-CT images to determine internal target volume (ITV) for fractionated stereotactic lung radiotherapy.
    Jin JY; Ajlouni M; Chen Q; Yin FF; Movsas B
    Radiother Oncol; 2006 Feb; 78(2):177-84. PubMed ID: 16376444
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Usefulness of FDG-PET/CT in the detection of pancreatic metastases from lung cancer.
    Sato M; Okumura T; Kaito K; Kiyoshima M; Asato Y; Uchiumi K; Iijima H; Hashimoto I; Kaburagi T; Amemiya R
    Ann Nucl Med; 2009 Jan; 23(1):49-57. PubMed ID: 19205838
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dynamic MRI, dynamic multidetector-row computed tomography (MDCT), and coregistered 2-[fluorine-18]-fluoro-2-deoxy-D-glucose-positron emission tomography (FDG-PET)/CT: comparative study of capability for management of pulmonary nodules.
    Ohno Y; Koyama H; Takenaka D; Nogami M; Maniwa Y; Nishimura Y; Ohbayashi C; Sugimura K
    J Magn Reson Imaging; 2008 Jun; 27(6):1284-95. PubMed ID: 18504748
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Diffusion weighted MRI and 18F-FDG PET/CT in non-small cell lung cancer (NSCLC): does the apparent diffusion coefficient (ADC) correlate with tracer uptake (SUV)?
    Regier M; Derlin T; Schwarz D; Laqmani A; Henes FO; Groth M; Buhk JH; Kooijman H; Adam G
    Eur J Radiol; 2012 Oct; 81(10):2913-8. PubMed ID: 22197090
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 49.